• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类原发性高血压的发病机制:一种识别病因及治疗的新方法。

Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy.

作者信息

Korner P I, Jennings G L, Esler M D

出版信息

J Hypertens Suppl. 1986 Oct;4(3):S149-53.

PMID:2878068
Abstract

In chronic renovascular hypertension the amplifier properties of the hypertrophied heart and vessels contribute considerably more to the maintenance of the elevated blood pressure (BP) than the basic underlying cause. This must also occur in chronic primary hypertension. Accordingly, we hypothesized that after reversal of hypertrophy by antihypertensive medication the cause(s) of hypertension should be easier to detect during the redevelopment of hypertension once medication was stopped, than in the chronic phase of the disorder. We have studied three groups of patients with moderate to severe hypertension in whom BP was controlled for (1) 1 month (2) 1 year and (3) 15 months to 5 years. The rate of subsequent redevelopment of hypertension between the series was inversely related to the duration of therapy, which was mostly with beta-blockers and diuretics. Redevelopment of hypertension was slowest after obtaining regression of both vascular hypertrophy and left ventricular hypertrophy (LVH). Preliminary findings suggest that sympathetic overactivity is present during the redevelopment phase in most patients. Our findings have suggested a new therapeutic strategy, where the effectiveness of non-pharmacological methods of controlling BP is enhanced by first causing regression of cardiovascular hypertrophy by drug treatment. Moderate regular exercise has proved to be an effective non-pharmacological antihypertensive method which has now maintained five patients at normal BP for 1 year, following an initial period of drug treatment.

摘要

在慢性肾血管性高血压中,肥厚的心脏和血管的放大特性对维持血压升高的作用,远超过根本病因。慢性原发性高血压也必然如此。因此,我们推测,在通过抗高血压药物使肥厚逆转后,一旦停药,高血压复发时,其病因应比疾病慢性期更容易检测。我们研究了三组中度至重度高血压患者,他们的血压分别控制了(1)1个月、(2)1年以及(3)15个月至5年。三组患者后续高血压复发率与治疗持续时间呈负相关,治疗主要使用β受体阻滞剂和利尿剂。在血管肥厚和左心室肥厚(LVH)均消退后,高血压复发最慢。初步研究结果表明,大多数患者在复发阶段存在交感神经过度活跃。我们的研究结果提示了一种新的治疗策略,即通过药物治疗首先使心血管肥厚消退,从而增强控制血压的非药物方法的有效性。适度的规律运动已被证明是一种有效的非药物抗高血压方法,在最初一段时间的药物治疗后,目前已有5名患者通过该方法维持血压正常达1年。

相似文献

1
Pathogenesis of human primary hypertension: a new approach to the identification of causal factors and to therapy.人类原发性高血压的发病机制:一种识别病因及治疗的新方法。
J Hypertens Suppl. 1986 Oct;4(3):S149-53.
2
A new approach to the identification of pathogenetic factors and to therapy in human primary hypertension.一种识别人类原发性高血压致病因素及进行治疗的新方法。
J Clin Hypertens. 1987 Jun;3(2):187-96.
3
[Regression of left heart hypertrophy in arterial hypertension: principles, experimental and clinical findings].[动脉高血压中左心室肥厚的消退:原理、实验及临床研究结果]
Z Kardiol. 1985;74 Suppl 7:153-69.
4
[Arterial hypertension and dyslipidemia in patients with chronic kidney disease (CKD). Anti-platelet aggregation. Goal oriented treatment].[慢性肾脏病(CKD)患者的动脉高血压和血脂异常。抗血小板聚集。目标导向治疗]
Nefrologia. 2008;28 Suppl 3:39-48.
5
Regression of cardiac hypertrophy with drug treatment in spontaneously hypertensive rats.自发性高血压大鼠经药物治疗后心脏肥大的消退
Med Biol. 1984;62(5):263-76.
6
Shifting trends in the pharmacologic treatment of hypertension in a Nigerian tertiary hospital: a real-world evaluation of the efficacy, safety, rationality and pharmaco-economics of old and newer antihypertensive drugs.尼日利亚一家三级医院高血压药物治疗的趋势变化:对新旧抗高血压药物的疗效、安全性、合理性和药物经济学的真实世界评估
J Hum Hypertens. 2003 Apr;17(4):277-85. doi: 10.1038/sj.jhh.1001538.
7
The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.氯沙坦降低高血压终点事件(LIFE)研究:原理、设计与方法。LIFE研究组
Am J Hypertens. 1997 Jul;10(7 Pt 1):705-13.
8
Hypertension in elderly--an overview.老年人高血压——综述
J Indian Med Assoc. 1999 Mar;97(3):96-101.
9
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.高血压左心室肥厚患者氯沙坦干预降低终点事件(LIFE)研究中的血压降低及降压药物使用情况
Curr Med Res Opin. 2007 Feb;23(2):259-70. doi: 10.1185/030079906X162854.
10
[Evaluation of the effectiveness of the long-term treatment of hypertension patients. I. Changes in hemodynamics and myocardial function].高血压患者长期治疗效果评估。I. 血流动力学及心肌功能变化
Ter Arkh. 1984;56(9):24-30.

引用本文的文献

1
Factors involved in the pathogenesis of hypertensive cardiovascular hypertrophy. A review.高血压性心血管肥大发病机制中的相关因素。综述。
Drugs. 1988;35 Suppl 5:6-26. doi: 10.2165/00003495-198800355-00003.